Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 20/20 | 1.00 |
| ▸ | MMP1 | P03956 | 14/20 | 1.00 |
| ▸ | MMP2 | P08253 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10118110 | 1.00 | MMP3 (1.00) | MMP3MMP1MMP2 | |
| SCHEMBL6953778 | 1.00 | MMP3 (1.00) | MMP3MMP1MMP2 | |
| SCHEMBL6957673 | 0.95 | MMP3 (0.90) | MMP3MMP1MMP2 | |
| SCHEMBL15061612 | 0.92 | MMP3 (0.84) | MMP3MMP1MMP2 | |
| SCHEMBL6949394 | 0.90 | MMP3 (0.82) | MMP3MMP1MMP2 | |
| SCHEMBL6950356 | 0.89 | MMP3 (0.81) | MMP3MMP1MMP2 | |
| SCHEMBL6956147 | 0.89 | MMP3 (1.00) | MMP3MMP1MMP2 | |
| SCHEMBL10118131 | 0.89 | MMP3 (1.00) | MMP3MMP1MMP2 | |
| SCHEMBL2679911 | 0.89 | MMP3 (1.00) | MMP3MMP1MMP2 | |
| SCHEMBL6952846 | 0.88 | MMP3 (0.80) | MMP3MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100119489-A1 | Stimulation of Pancreatic Beta Cell Proliferation | STOFFEL MARKUS | 2010-05-13 | — | — | US | claimed |
| EP-1896605-A2 | STIMULATION OF PANCREATIC B CELL PROLIFERATION | The Rockefeller University (US) | 2008-03-12 | — | — | EP | claimed |
| WO-2006133333-A2 | STIMULATION OF PANCREATIC B CELL PROLIFERATION | THE ROCKEFELLER UNIVERSITY (US) | 2006-12-14 | — | — | WO | claimed |
| EP-0900211-B1 | THIADIAZOLYL(THIO)UREAS USEFUL AS MATRIX METALLOPROTEASE INHIBITORS | UPJOHN CO (US) | 2003-07-02 | — | — | EP | claimed |
| EP-0900211-A1 | THIADIAZOLYL(THIO)UREAS USEFUL AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-10 | — | — | EP | claimed |
| WO-1997040031-A1 | THIADIAZOLYL(THIO)UREAS USEFUL AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1997-10-30 | — | — | WO | claimed |
| EP-2282719-B1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | REVALESIO CORP (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9745567-B2 | Compositions and methods for treating multiple sclerosis | REVALESIO CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-8828977-B2 | Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor | DISCOGEN, LLC (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2605013-A1 | Stimulation of pancreatic beta-cell proliferation | THE ROCKEFELLER UNIVERSITY (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20120114702-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | REVALESIO CORPORATION | 2012-05-10 | — | — | US | disclosed |
| US-20100119489-A1 | Stimulation of Pancreatic Beta Cell Proliferation | STOFFEL MARKUS | 2010-05-13 | — | — | US | disclosed |
| EP-1986657-A2 | METHOD OF TREATING A SUBJECT SUFFERING FROM DEGENERATIVE DISC DISEASE USING A MATRIX METALLOPROTEASE INHIBITOR | Discogen, LLC (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20040048803-A1 | Compounds and methods for the modulation of CD154 | PHILLIPS DAVID (US) | 2004-03-11 | — | — | US | disclosed |
| EP-0900211-B1 | THIADIAZOLYL(THIO)UREAS USEFUL AS MATRIX METALLOPROTEASE INHIBITORS | UPJOHN CO (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002089730-A2 | COMPOUNDS AND METHODS FOR THE MODULATION OF CD154 | THE CENTER FOR BLOOD RESEARCH, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
| US-20020165166-A1 | Compounds and methods for the modulation of CD154 | CBR INSTITUTE FOR BIOMEDICAL RESEARCH, INC. | 2002-11-07 | — | — | US | disclosed |
| EP-0900211-A1 | THIADIAZOLYL(THIO)UREAS USEFUL AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5847148-A | Thiadiazole derivatives useful for the treatment of diseases related to connective tissue degradation | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1997040031-A1 | THIADIAZOLYL(THIO)UREAS USEFUL AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114702-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | CHRM3, CHRNG, GRK3 | MMP3 3032/4885MMP1 1698/4885MMP2 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.